The Readout
Your guide to what’s new in biotech. Sign up for the newsletter here.
Most Read
Sage’s debatable data, Hahn’s retort, & biotech’s mixed record in June
CRISPR for cancer, Biogen’s $800m flyer, & Hahn’s VC future
FDA conspiracy theories, closing the Covid vaccine gap, & how to value a Vant
CureVac’s any-day-now data, more FDA conservatism, & a lawsuit about coupons
Pfizer’s 95% vaccine efficacy, disappointment in ALS, & FDA promises of transparency
Trump’s drug EO, a $1 billion Biogen deal, & the case for inaccuracy
Covid-19 vaccine data from Novavax & the future of peanut allergy treatment
All Coverage